MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/qai.0000000000003027

Медицинская библиотека · Journal of acquired immune deficiency syndromes (1999) · 2022

High Levels of Pretreatment HIV-1 Drug Resistance Mutations Among South African Women Who Acquired HIV During a Prospective Study.

Beesham Ivana, Parikh Urvi M, Mellors John W, Joseph Davey Dvora L, Heffron Renee, Palanee-Phillips Thesla, Bosman Shannon L, Beksinska Mags, Smit Jennifer, Ahmed Khatija, Makkan Heeran, Selepe Pearl, Louw Cheryl, Kotze Philip, Hofmeyr G Justus, Singata-Madliki Mandisa, Rees Helen, Baeten Jared M, Wallis Carole

СтатьяПоддержка исследования: вне правительства СШАПоддержка правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Pretreatment HIV drug resistance (PDR) undermines individual treatment success and threatens the achievement of UNAIDS 95-95-95 targets. In many African countries, limited data are available on PDR as detection of recent HIV infection is uncommon and access to resistance testing is limited. We describe the prevalence of PDR among South African women with recent HIV infection from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial.

METHODS

HIV-uninfected, sexually active women, aged 18-35 years, and seeking contraception were enrolled in the ECHO Trial at sites in South Africa, from 2015 to 2018. HIV testing was done at trial entry and repeated quarterly. We tested stored plasma samples collected at HIV diagnosis from women who seroconverted during follow-up and had a viral load >1000 copies/mL for antiretroviral resistant mutations using a validated laboratory-developed population genotyping assay, which sequences the full protease and reverse transcriptase regions. Mutation profiles were determined using the Stanford Drug Resistance Database.

RESULTS

We sequenced 275 samples. The median age was 23 years, and majority (98.9%, n = 272) were infected with HIV-1 subtype C. The prevalence of surveillance drug resistance mutations (SDRMs) was 13.5% (n = 37). Nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations were found in 12.4% of women (n = 34). Few women had NRTI (1.8%, n = 5) and protease inhibitor (1.1%, n = 3) mutations. Five women had multiple NRTI and NNRTI SDRMs.

CONCLUSIONS

The high levels of PDR, particularly to NNRTIs, strongly support the recent change to the South African national HIV treatment guidelines to transition to a first-line drug regimen that excludes NNRTIs.

Для цитирования: Beesham Ivana, Parikh Urvi M, Mellors John W, Joseph Davey Dvora L, Heffron Renee, Palanee-Phillips Thesla, Bosman Shannon L, Beksinska Mags, Smit Jennifer, Ahmed Khatija, Makkan Heeran, Selepe Pearl, Louw Cheryl, Kotze Philip, Hofmeyr G Justus, Singata-Madliki Mandisa, Rees Helen, Baeten Jared M, Wallis Carole. High Levels of Pretreatment HIV-1 Drug Resistance Mutations Among South African Women Who Acquired HIV During a Prospective Study.. Journal of acquired immune deficiency syndromes (1999). 2022. DOI: 10.1097/qai.0000000000003027.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.